Dr Reddy's Labs Q2 Preview: Profits may decline 7%, revenues to rise 12%

Quick Summary:

Overall, DRRD's sales are anticipated to grow by 14 per cent Y-o-Y (+2 per cent Q-o-Q) in Q2 FY25.

Reddy's revenue and Ebitda to grow by 10 per cent and 9 per cent year-on-year, respectively, with Ebitda margins at 28.8 per cent for Q2FY25.

The India business is anticipated to grow by 19 per cent year-on-year, fueled by an 11 per cent organic growth and approximately Rs 1 billion from the vaccine business.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: India

Topics: Dr reddys labs q2 results Sensex Q2 results Pharma sector Dr reddys labs Dr reddys labs share price today Dr reddys labs preview q2 Dr reddys labs profit Nifty Dr reddys labs share price Q2 results today Market news Stock market Dr reddys labs q2 results preview Pharma Dr reddys labs stock price Dr reddys labs revenue

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-04 @ 10:00:32 (1 days ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 780 words

Reading Time: 5 minutes read

Sentences: 33 lines

Sentence Length: 24 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 23388573

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 340 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 2 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions